Correspondence| Volume 65, 104002, September 2022

Download started.


Outcomes of Ublituximab compared to Teriflunomide for relapsing multiple sclerosis: A meta-analysis


      Ublituximab is an anti-CD20 antibody that immunomodulates B-cells for relapsing multiple sclerosis (MS). With limited therapeutics available, this original meta-analysis seeks to determine the effect size (using RevMan 5.4.1) for annualized relapse rate (ARR), MRI outcomes and no evidence of disease activity (NEDA) by two years post-initiation of Ublituximab. Two RCTs (N = 1094) reveal Cohen's d for ARR= -0.17 (P = 0.006) favoring Ublituximab. MRI-tested, week 96 findings of T1 (Cohen's d= -0.43, P < 0.00001) and T2 (Cohen's d= -0.55; P < 0.00001) lesions favor Ublituximab compared to Teriflunomide. Less disease activity was reported in the Ublituximab group (OR=3.33, P < 0.00001). Further trials are required to corroborate findings.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Multiple Sclerosis and Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Lee D.S.W.
        • Rojas O.L.
        • Gommerman J.L.
        B cell depletion therapies in autoimmune disease: advances and mechanistic insights.
        Nat. Rev. Drug Discov. 2021; 20: 179-199
        • Cotchett K.R.
        • Dittel B.N.
        • Obeidat A.Z.
        Comparison of the efficacy and safety of anti-CD20 B cells depleting drugs in multiple sclerosis.
        Mult. Scler. Relat. Disord. 2021; 49102787
      1. TG Therapeutics Announces FDA Acceptance of Biologics [Internet]. [cited 2022 May 9]. Available from:

      2. Long-Term Treatments for Multiple Sclerosis | MSAA [Internet]. [cited 2022 May 9]. Available from:

      3. Cochrane. RevMan | Cochrane Training [Internet]. [cited 2021 Jun 16]. Available from:

      4. Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) (ULTIMATE 1) [Internet]. [cited 2022 May 9]. Available from:

      5. Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) (ULTIMATE II) [Internet]. [cited 2022 May 9]. Available from:

        • Fox E.
        • Lovett-Racke A.E.
        • Gormley M.
        • Liu Y.
        • Petracca M.
        • Cocozza S.
        • et al.
        A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis.
        Mult. Scler. J. 2021; 27: 420-429
        • Steinman L.
        • Alvarez E.
        • Fox E.
        • Hartung H.P.
        • Qian P.
        • Wray S.
        • et al.
        Phase 3 results of the ULTIMATE I & II global studies: ublituximab versus teriflunomide in relapsing multiple sclerosis.
      6. Steinman L., Fox E., Hartung H.P., Alvarez E., Qian P., Wray S., et al. Efficacy and safety of Ublituximab versus Teriflunomide in relapsing multiple sclerosis: results of the Phase 3 ULTIMATE I and II trials (4494). AAN Enterprises; 2021.

        • Krajnc N.
        • Bsteh G.
        • Berger T.
        • Mares J.
        • Hartung H.P.
        Monoclonal antibodies in the treatment of relapsing multiple sclerosis: an overview with emphasis on pregnancy, vaccination, and risk management.
        Neurotherapeutics. 2022; : 1-21